| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Rory R. Koenen | Q37829140 |
| Christian Weber | Q37838769 | ||
| P2860 | cites work | A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice | Q61386199 |
| Platelets regulate CD4+ T-cell differentiation via multiple chemokines in humans | Q61684165 | ||
| Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis | Q63915146 | ||
| Interleukin-8 antagonists generated by N-terminal modification | Q70635998 | ||
| Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence | Q79175268 | ||
| Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis | Q79711302 | ||
| CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice | Q80120098 | ||
| Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo | Q80976739 | ||
| A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis | Q82837990 | ||
| Chemokines in health and disease | Q83169012 | ||
| Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region | Q83236917 | ||
| Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells | Q83305041 | ||
| CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice | Q84741014 | ||
| Therapy with nonglycosaminoglycan-binding mutant CCL7: a novel strategy to limit allograft inflammation | Q84967596 | ||
| Platelets enhance lymphocyte adhesion and infiltration into arterial thrombus | Q85025568 | ||
| Chemokine receptor 7 knockout attenuates atherosclerotic plaque development | Q85156583 | ||
| Chemokines take centre stage in vascular biology | Q95787636 | ||
| Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme | Q24304041 | ||
| CCR7 and its ligands: balancing immunity and tolerance | Q24316090 | ||
| The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity | Q24632813 | ||
| Structural Basis of Chemokine Sequestration by a Tick Chemokine Binding Protein: The Crystal Structure of the Complex between Evasin-1 and CCL3 | Q27658814 | ||
| CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival | Q28506756 | ||
| CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration | Q28581476 | ||
| Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection | Q28752308 | ||
| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
| The many roles of chemokines and chemokine receptors in inflammation | Q29618880 | ||
| Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2 | Q29622852 | ||
| Chemokines as mediators of tumor angiogenesis and neovascularization | Q30427886 | ||
| CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall | Q30444644 | ||
| Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis | Q30497499 | ||
| Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes | Q30497539 | ||
| Dose-response met-RANTES treatment of experimental periodontitis: a narrow edge between the disease severity attenuation and infection control | Q31028208 | ||
| The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. | Q31725223 | ||
| Engineering novel binding proteins from nonimmunoglobulin domains | Q33224761 | ||
| Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice | Q33236495 | ||
| The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4. | Q33304448 | ||
| The chemokine system: redundancy for robust outputs | Q33650445 | ||
| Chemokines and asthma: redundancy of function or a coordinated effort? | Q33753439 | ||
| Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues | Q34059219 | ||
| Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNgamma-producing effector cells | Q34131442 | ||
| The immune system in atherosclerosis | Q34164644 | ||
| Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis | Q34652627 | ||
| Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines | Q34762409 | ||
| Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis | Q34828549 | ||
| Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression | Q34876397 | ||
| Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. | Q35088170 | ||
| Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice | Q35151086 | ||
| Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques | Q35250952 | ||
| Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata | Q35251005 | ||
| CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice | Q35572404 | ||
| Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites | Q35664094 | ||
| Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells | Q35698582 | ||
| The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. | Q35732501 | ||
| Chemokine blockers--therapeutics in the making? | Q36323784 | ||
| Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity | Q36403130 | ||
| CXCR4-CCR5: a couple modulating T cell functions | Q36786977 | ||
| An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. | Q36882279 | ||
| Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide | Q36976659 | ||
| The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models | Q37282249 | ||
| Chemokine receptor antagonists: overcoming developmental hurdles | Q37349685 | ||
| Platelet-mediated enhancement of leukocyte adhesion | Q37359979 | ||
| A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice | Q37377448 | ||
| Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. | Q37431503 | ||
| Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis | Q37435783 | ||
| Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. | Q37470294 | ||
| Anti-inflammatory therapeutics for the treatment of atherosclerosis | Q37626768 | ||
| Chemokines in the vascular inflammatory response of atherosclerosis | Q37652971 | ||
| Therapeutic targeting of chemokine interactions in atherosclerosis | Q37684793 | ||
| Phagocyte partnership during the onset and resolution of inflammation. | Q37760424 | ||
| Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. | Q37819144 | ||
| Heterophilic chemokine receptor interactions in chemokine signaling and biology | Q37819146 | ||
| Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function | Q37827607 | ||
| Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients | Q39157923 | ||
| Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo | Q39615447 | ||
| Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice | Q39639458 | ||
| A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis | Q39763545 | ||
| Ticks produce highly selective chemokine binding proteins with antiinflammatory activity | Q40063162 | ||
| Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity | Q40212535 | ||
| Three-dimensional structures of alpha and beta chemokines. | Q40569716 | ||
| The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. | Q40674317 | ||
| Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury | Q40703820 | ||
| The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation | Q41175846 | ||
| Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. | Q41229926 | ||
| Chemokine research moves on. | Q41830371 | ||
| Homocysteine up-regulates vascular transmembrane chemokine CXCL16 and induces CXCR6+ lymphocyte recruitment in vitro and in vivo | Q41933923 | ||
| Cellular dysfunction in inflammatory-related vascular disorders' review series. The inflammatory process: a new dimension of a 19 century old story | Q42389614 | ||
| CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells | Q42767496 | ||
| Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis | Q43222603 | ||
| Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice | Q43489161 | ||
| Early application of Met-RANTES ameliorates chronic allograft nephropathy | Q43889573 | ||
| Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice | Q44680905 | ||
| Overcoming hurdles in developing successful drugs targeting chemokine receptors | Q46441158 | ||
| HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice | Q46766122 | ||
| Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses | Q46806608 | ||
| Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis | Q46897070 | ||
| CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice | Q47375281 | ||
| A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury | Q47438278 | ||
| Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study | Q47927665 | ||
| An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. | Q51778397 | ||
| Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. | Q51979776 | ||
| Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. | Q52583321 | ||
| Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. | Q53378752 | ||
| Transmembrane chemokines: versatile 'special agents' in vascular inflammation. | Q53555496 | ||
| Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. | Q54658035 | ||
| Glycosaminoglycans Mediate Cell Surface Oligomerization of Chemokines | Q57019212 | ||
| A New Monocyte Chemotactic Protein-1/Chemokine CC Motif Ligand-2 Competitor Limiting Neointima Formation and Myocardial Ischemia/Reperfusion Injury in Mice | Q57574588 | ||
| Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium | Q57574602 | ||
| Natural regulatory T cells control the development of atherosclerosis in mice | Q58149268 | ||
| Single Administration of the CXC Chemokine-Binding Protein Evasin-3 During Ischemia Prevents Myocardial Reperfusion Injury in Mice | Q58197658 | ||
| P433 | issue | 12 | |
| P921 | main subject | atherosclerosis | Q12252367 |
| peptide | Q172847 | ||
| chemokine | Q421866 | ||
| P304 | page(s) | 713-725 | |
| P577 | publication date | 2011-10-28 | |
| 2011-12-01 | |||
| P1433 | published in | EMBO Molecular Medicine | Q15817279 |
| P1476 | title | Chemokines: established and novel targets in atherosclerosis | |
| P478 | volume | 3 |
| Q41961508 | A cytofluorometric study of membrane rafts in human monocyte subsets in atherosclerosis. |
| Q60908132 | A functional variant of enhances macrophage recruitment and inflammatory response via TGF-β signal activation in Thoracic aortic aneurysm and dissection |
| Q41024442 | A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. |
| Q37270341 | Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo |
| Q27677101 | Alternative C-Terminal Helix Orientation Alters Chemokine Function: STRUCTURE OF THE ANTI-ANGIOGENIC CHEMOKINE, CXCL4L1 |
| Q39051784 | Anti-inflammatory drugs as promising cardiovascular treatments. |
| Q38349757 | Anti-inflammatory therapies for atherosclerosis |
| Q38423257 | Atherosclerosis and the role of immune cells |
| Q35661830 | Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice |
| Q36817578 | Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. |
| Q55640686 | Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis. |
| Q42862270 | Chemokines and Their Receptors Are Key Players in the Orchestra That Regulates Wound Healing |
| Q26801787 | Chemokines and their receptors in Atherosclerosis |
| Q42016510 | Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction |
| Q102388720 | Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting |
| Q37002637 | ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK |
| Q41781398 | Effects of Myeloperoxidase-Induced Oxidation on Antiatherogenic Functions of High-Density Lipoprotein. |
| Q36596629 | Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice |
| Q38066291 | Hypercholesterolemia links hematopoiesis with atherosclerosis. |
| Q58197587 | Immunological aspects of atherosclerosis |
| Q54378142 | Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. |
| Q38083555 | Inflammation and immune system interactions in atherosclerosis |
| Q93046647 | Isolation, culturing and gene expression profiling of inner mass cells from stable and vulnerable carotid atherosclerotic plaques |
| Q35992029 | Leukocyte chemoattractant receptor FPR2 may accelerate atherogenesis |
| Q64915291 | Low-Density Lipoprotein-Reactive T Cells Regulate Plasma Cholesterol Levels and Development of Atherosclerosis in Humanized Hypercholesterolemic Mice. |
| Q35600904 | Lymphocyte migration into atherosclerotic plaque |
| Q36403272 | NG2 Proteoglycan Ablation Reduces Foam Cell Formation and Atherogenesis via Decreased Low-Density Lipoprotein Retention by Synthetic Smooth Muscle Cells |
| Q34609062 | PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis |
| Q90258526 | Physical Activity, Immune System, and the Microbiome in Cardiovascular Disease |
| Q38038134 | Platelets: key players in vascular inflammation |
| Q38403881 | Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies |
| Q36817646 | Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease |
| Q27023950 | Regulation of atherogenesis by chemokine receptor CCR6 |
| Q27003124 | Regulation of atherogenesis by chemokines and chemokine receptors |
| Q35062502 | Role of chemokines in promoting instability of coronary atherosclerotic plaques and the underlying molecular mechanism |
| Q92724115 | Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases |
| Q92850685 | Systematic analysis of long non-coding RNA and mRNA expression changes in ApoE-deficient mice during atherosclerosis |
| Q48139308 | The chemokine receptor CX3CR1 coordinates monocyte recruitment and endothelial regeneration after arterial injury |
| Q38048775 | The complex regulation of TGF-β in cardiovascular disease |
| Q41709158 | The regulation of immune cells by Lactobacilli: a potential therapeutic target for anti-atherosclerosis therapy |
| Q89798665 | Tick Saliva Protein Evasin-3 Allows for Visualization of Inflammation in Arteries through Interactions with CXC-Type Chemokines Deposited on Activated Endothelium |
| Q36090029 | Touch of chemokines |
| Q48317785 | [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. |
Search more.